MPPE1 and neoplasm: Prospective trials should embed these assays with prespecified analytical thresholds, transparent batch correction, cross-platform validations, and on-treatment pharmacodynamic criteria that attribute benefit to myeloid modulation (depletion/reprogramming of suppressive states, restoration of cDC1 circuits, remodeling of macrophage–tumor borders) (46–49, 78–81).